2024
690TiP HERTHENA-PanTumor01: A global phase II trial of HER3-DXd in metastatic solid tumors
Powles T, Bhatia A, Burtness B, Kogawa T, Nishina T, Nakayama I, Fountzilas C, Castillo D, Mckean M, Meric-Bernstam F, Colombo N, Smithy J, Fayette J, Chandra S, Sternberg D, Sullivan K, Yueh S, Clinthorne G, Kudchadkar R, Hayashi H. 690TiP HERTHENA-PanTumor01: A global phase II trial of HER3-DXd in metastatic solid tumors. Annals Of Oncology 2024, 35: s534-s535. DOI: 10.1016/j.annonc.2024.08.2161.Peer-Reviewed Original ResearchThe NAVigate-HPV Registry: A comprehensive biomarker evidence base for HPV-driven cancers.
Roof S, Hanna G, Rettig E, Routman D, Holsinger F, Kalman N, Bhatia A, Patel M, Jabalee J, Yom S, Baliga S, Raben A, Sims J, Kaczmar J, Bhayani M, Berger B, Del Vecchio Fitz C. The NAVigate-HPV Registry: A comprehensive biomarker evidence base for HPV-driven cancers. Journal Of Clinical Oncology 2024, 42: e15045-e15045. DOI: 10.1200/jco.2024.42.16_suppl.e15045.Peer-Reviewed Original ResearchHPV-driven cancersHPV-related cancersHuman papillomavirusClinical dataHead and neckClinical outcome dataBlood-based assayPrecision cancer medicineClinical careRoutine clinical careDNA scoreUterine cervixAcademic medical facilityImprove patient outcomesAnal canalClinicopathological featuresEligible subjectsU.S. cancer centersBlood testsOncogenic driversCancer CenterTherapeutic approachesTumor biomarkersPatientsCancer medicineHERTHENA-PanTumor01: A global, multicohort, phase 2 trial of HER3-DXd in relapsed/refractory metastatic solid tumors.
Bhatia A, Hayashi H, Kogawa T, Nishina T, Fountzilas C, Castillo D, McKean M, Colombo N, Smithy J, Fayette J, Chandra S, Powles T, Kudchadkar R, Sternberg D, Sullivan K, Yueh S, Clinthorne G, Burtness B. HERTHENA-PanTumor01: A global, multicohort, phase 2 trial of HER3-DXd in relapsed/refractory metastatic solid tumors. Journal Of Clinical Oncology 2024, 42: tps3164-tps3164. DOI: 10.1200/jco.2024.42.16_suppl.tps3164.Peer-Reviewed Original ResearchHead and neck squamous cell cancerHuman epidermal growth factor receptor 3Platinum-based chemotherapyHER3-DXdPhase 2 trialAntibody-drug conjugatesSolid tumorsHuman anti-HER3 monoclonal antibodyAnti-HER3 monoclonal antibodyAnti-PD-(L)1 therapyGastric cancerHER2-negative gastric cancerTopoisomerase I inhibitor payloadAssociated with poor clinical outcomesEpidermal growth factor receptor 3Anti-HER3 antibodiesGastroesophageal junction cancerHER2+ cancersMetastatic solid tumorsMetastatic breast cancerSquamous cell cancerBRAF wild-typePoor clinical outcomesMultiple tumor typesAcral subtype
2023
Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer
Bauman J, Saba N, Roe D, Bauman J, Kaczmar J, Bhatia A, Muzaffar J, Julian R, Wang S, Bearelly S, Baker A, Steuer C, Giri A, Burtness B, Centuori S, Caulin C, Klein R, Saboda K, Obara S, Chung C. Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer. Journal Of Clinical Oncology 2023, 41: 3851-3862. PMID: 36977289, DOI: 10.1200/jco.22.01994.Peer-Reviewed Original ResearchConceptsMedian progression-free survivalProgression-free survivalObjective response rateRecurrent/metastatic headCMET overexpressionMetastatic headCombination armAntiepidermal growth factor receptor monoclonal antibodyNoncomparative phase II studyRecurrent/metastatic HNSCCRandomized phase II trialEnd pointNeck squamous cell carcinomaHPV negative subgroupPhase II studyPrimary end pointSecondary end pointsHPV-positive diseaseHuman papillomavirus (HPV) statusMajor prognostic factorPhase II trialKey eligibility criteriaSquamous cell carcinomaReceptor monoclonal antibodyHPV-negative HNSCCTreating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update
Bhatia A, Burtness B. Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update. Drugs 2023, 83: 217-248. PMID: 36645621, DOI: 10.1007/s40265-023-01835-2.Commentaries, Editorials and LettersConceptsNeck cancerRecurrent/metastatic settingImmune checkpoint inhibitor nivolumabNeck squamous cell carcinomaAge of immunotherapyLate stage HNSCCImmune checkpoint inhibitionPlatinum-containing chemotherapyFirst-line treatmentGrowth factor receptor overexpressionCheckpoint inhibitor nivolumabSquamous cell carcinomaEpidermal growth factor receptor (EGFR) overexpressionPathogenesis of HNSCCTreatment of patientsTreatment of HNSCCManagement of headMonoclonal antibody cetuximabCurative intentPalliative chemotherapyAdvanced diseaseInhibitor nivolumabLocoregional failureMetastatic settingMultimodality therapy
2022
656MO Phase I study of M6620 (VX-970, berzosertib) in combination with cisplatin and XRT in patients with locally advanced head and neck squamous cell carcinoma
Bhatia A, Chen Z, Bruce J, Steuer C, Zandberg D, Riess J, Mitchell D, Davis T, Patel M, Kaur V, Arnold S, Owonikoko T. 656MO Phase I study of M6620 (VX-970, berzosertib) in combination with cisplatin and XRT in patients with locally advanced head and neck squamous cell carcinoma. Annals Of Oncology 2022, 33: s842. DOI: 10.1016/j.annonc.2022.07.780.Peer-Reviewed Original ResearchTargeting Epidermal Growth Factor Receptor in Head and Neck Cancer
Bhatia A. Targeting Epidermal Growth Factor Receptor in Head and Neck Cancer. The Cancer Journal 2022, 28: 331-338. PMID: 36165720, DOI: 10.1097/ppo.0000000000000623.Peer-Reviewed Original ResearchConceptsNeck squamous cell carcinomaSquamous cell carcinomaEpidermal growth factor receptorGrowth factor receptorSystemic therapyCell carcinomaEpidermal growth factor receptor targetingFactor receptorMainstay of managementRational drug combinationsMost patientsDisease recurrenceDeath-1Neck cancerDisease outcomeDrug combinationsPatientsNovel drugsReceptor targetingSubstantial proportionRadiation techniquesPreclinical scienceCarcinomaTherapyReceptorsA phase II/III trial of chemotherapy plus cetuximab versus chemotherapy plus bevacizumab versus atezolizumab plus bevacizumab following progression on immune checkpoint inhibition in recurrent/metastatic head and neck cancers: ECOG-ACRIN EA3202.
Bhatia A, Flamand Y, Johnson J, Ishizuka J, Duan F, Tang M, Karivedu V, Subramaniam R, Burtness B. A phase II/III trial of chemotherapy plus cetuximab versus chemotherapy plus bevacizumab versus atezolizumab plus bevacizumab following progression on immune checkpoint inhibition in recurrent/metastatic head and neck cancers: ECOG-ACRIN EA3202. Journal Of Clinical Oncology 2022, 40: tps6098-tps6098. DOI: 10.1200/jco.2022.40.16_suppl.tps6098.Peer-Reviewed Original ResearchProgression-free survivalVascular endothelial growth factorM HNSCCOverall survivalPrimary endpointExperimental armControl armHigher treatment-related adverse eventsPhase II/III trialsOne-sided alpha levelRecurrent/metastatic headTreatment-related adverse eventsEffector T cell responsesMyeloid-derived suppressor cellsPhase II/IIIPhase IIStratified log-rank testEfficacy of atezolizumabPlatinum-doublet chemotherapyImmune checkpoint inhibitionFirst-line pembrolizumabAnti-tumor immunityPhase IIIDendritic cell maturationPhase III evaluationCemiplimab for Orbital Squamous Cell Carcinoma in 11 Cases
Steren B, Burtness B, Bhatia A, Demirci H, Shinder R, Yoo D, Tse B, Pointdujour-Lim R. Cemiplimab for Orbital Squamous Cell Carcinoma in 11 Cases. Ophthalmic Plastic And Reconstructive Surgery 2022, 38: 496-502. PMID: 35502804, DOI: 10.1097/iop.0000000000002190.Peer-Reviewed Original ResearchConceptsOrbital squamous cell carcinomaSquamous cell carcinomaCell carcinomaImmune checkpoint inhibitorsMulti-institutional seriesSignificant side effectsCheckpoint inhibitorsPatient characteristicsComplete responseClinical featuresStudy cohortOrbital exenterationCemiplimabDrug dosingSide effectsPatientsCarcinomaTreatmentExenterationRegimenResponseDosingCohortWeeksCessationEfficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer with a focus on elderly or frail patients
Forman R, Deshpande H, Burtness B, Bhatia AK. Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer with a focus on elderly or frail patients. Head & Neck 2022, 44: 1777-1786. PMID: 35488876, DOI: 10.1002/hed.27077.Peer-Reviewed Original ResearchConceptsRECIST response rateProgression-free survivalMetastatic/recurrent diseaseOverall survivalInduction chemotherapyRecurrent diseaseNeck cancerMetastatic/recurrent headPFS/overall survivalMean progression-free survivalSuccessful induction rateMean overall survivalPercent of patientsCases of metastasisFrail subsetWeekly paclitaxelFrail patientsAdult patientsElderly patientsPerformance statusRecurrent headInduction cohortInduction groupPatientsRecurrent group
2021
Concurrent development of high-stage cutaneous squamous cell carcinoma during complete response of metastatic cutaneous squamous cell carcinoma to programmed cell death protein 1 blockade with cemiplimab
Siegel JD, Bhatia A, Ko CJ, Christensen SR. Concurrent development of high-stage cutaneous squamous cell carcinoma during complete response of metastatic cutaneous squamous cell carcinoma to programmed cell death protein 1 blockade with cemiplimab. JAAD Case Reports 2021, 18: 23-25. PMID: 34778502, PMCID: PMC8577130, DOI: 10.1016/j.jdcr.2021.10.009.Peer-Reviewed Original ResearchRandomized phase II trial of ficlatuzumab with or without cetuximab in pan-refractory, advanced head and neck squamous cell carcinoma (HNSCC).
Bauman J, Saba N, Roe D, Bauman J, Kaczmar J, Bhatia A, Muzaffar J, Julian R, Wang S, Bearelly S, Baker A, Steuer C, Giri A, Burtness B, Centuori S, Caulin C, Saboda K, Obara S, Chung C. Randomized phase II trial of ficlatuzumab with or without cetuximab in pan-refractory, advanced head and neck squamous cell carcinoma (HNSCC). Journal Of Clinical Oncology 2021, 39: 6015-6015. DOI: 10.1200/jco.2021.39.15_suppl.6015.Peer-Reviewed Original ResearchMedian progression-free survivalOverall response rateHepatocyte growth factorAdvanced HNSCCPartial responsePrimary endpointEvaluable subjectsHPV statusRecurrent/metastatic HNSCCAnti-EGFR monoclonal antibodiesNeck squamous cell carcinomaMajor prognostic variablesPerformance status 0Phase II trialProgression-free survivalNon-comparative trialsSquamous cell carcinomaConfidence intervalsPhase III investigationFC combinationDual pathway inhibitionLFT elevationsPFS endpointPrior cetuximabStatus 0Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer in elderly or frail patients.
Forman R, Bhatia A, Burtness B. Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer in elderly or frail patients. Journal Of Clinical Oncology 2021, 39: 6042-6042. DOI: 10.1200/jco.2021.39.15_suppl.6042.Peer-Reviewed Original ResearchProgression-free survivalOverall survivalInduction chemotherapyFrail patientsAdverse effectsMean progression-free survivalNeck squamous cell carcinomaP16-positive diseasePrimary end pointRECIST response rateCommon adverse effectsMean overall survivalRetrospective observational studyCommon tumor siteCommon reason patientsSquamous cell carcinomaCases of metastasisDose interruptionWeekly paclitaxelAdvanced diseaseGastrointestinal symptomsMetastatic headPrior radiationChart reviewElderly patientsCombinations of immunotherapy and radiation therapy in head and neck squamous cell carcinoma: a narrative review
Hayman TJ, Bhatia AK, Jethwa KR, Young MR, Park HS. Combinations of immunotherapy and radiation therapy in head and neck squamous cell carcinoma: a narrative review. Translational Cancer Research 2021, 10: 2571-2585. PMID: 35116571, PMCID: PMC8798834, DOI: 10.21037/tcr-20-2096.Peer-Reviewed Original ResearchNeck squamous cell carcinomaSquamous cell carcinomaRadiation therapyCell carcinomaImmune responseNon-surgical treatment modalitiesCell death ligand 1Cell death protein 1Cancer-directed therapyCombination of immunotherapyAnti-tumor responseDeath ligand 1Death protein 1Adaptive immune responsesAdaptive immune systemAdvanced HNSCCAdvanced diseaseMetastatic settingPostoperative settingSystemic therapyImmunomodulatory effectsTreatment modalitiesRecurrent/Clinical trialsClinical data
2020
Randomized, phase II study of ficlatuzumab with or without cetuximab in patients with pan-refractory, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Bauman J, Roe D, Saba N, Bauman J, Kaczmar J, Burtness B, Muzaffar J, Julian R, Wang S, Bearelly S, Baker A, Steuer C, Bhatia A, Giri A, Caulin C, Stabile L, Centuori S, Chung C. Randomized, phase II study of ficlatuzumab with or without cetuximab in patients with pan-refractory, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Journal Of Clinical Oncology 2020, 38: tps6594-tps6594. DOI: 10.1200/jco.2020.38.15_suppl.tps6594.Peer-Reviewed Original ResearchProgression-free survivalOverall response rateM HNSCCPhase II trialHepatocyte growth factorII trialCetuximab resistanceMulticenter phase II trialRecurrent/metastatic headTotal peripheral T cellsRandomized phase II trialExpression of HGFPoor progression-free survivalNeck squamous cell carcinomaPeripheral immune profileKey secondary endpointPhase II studyKey eligibility criteriaSquamous cell carcinomaPeripheral T cellsPI3K/AktIgG1 monoclonal antibodyTwo-arm designECOG 0EGFR monotherapyAdjuvant external beam radiotherapy for surgically resected, nonmetastatic anaplastic thyroid cancer
Saeed NA, Kelly JR, Deshpande HA, Bhatia AK, Burtness BA, Judson BL, Mehra S, Edwards HA, Yarbrough WG, Peter PR, Holt EH, Decker RH, Husain ZA, Park HS. Adjuvant external beam radiotherapy for surgically resected, nonmetastatic anaplastic thyroid cancer. Head & Neck 2020, 42: 1031-1044. PMID: 32011055, DOI: 10.1002/hed.26086.Peer-Reviewed Original ResearchConceptsAnaplastic thyroid cancerLonger OSAdjuvant EBRTThyroid cancerAdjuvant external beam radiotherapyNational Cancer DatabaseExternal beam radiotherapyConcurrent chemoradiationConcurrent chemotherapyImproved survivalMedian ageCancer DatabaseRetrospective analysisBeam radiotherapyEBRTChemotherapyPatientsCancerUVAChemoradiationResectionRadiotherapy
2019
Clinical Outcomes of Head and Neck Cancer Patients Who Undergo Resection, But Forgo Adjuvant Therapy
LOGANADANE G, KANN BH, PARK HS, JOHNSON SB, MEHRA S, JUDSON BL, BHATIA A, BELKACEMI Y, YARBROUGH WG, BURTNESS B, HUSAIN ZA. Clinical Outcomes of Head and Neck Cancer Patients Who Undergo Resection, But Forgo Adjuvant Therapy. Anticancer Research 2019, 39: 4885-4890. PMID: 31519591, DOI: 10.21873/anticanres.13674.Peer-Reviewed Original ResearchConceptsLocoregional recurrence-free survivalAdjuvant therapyNeck squamous cell carcinomaOutcomes of patientsRecurrence-free survivalSquamous cell carcinomaNeck cancer patientsHNSCC patientsClinical outcomesRecurrence rateCell carcinomaMean TTPCancer patientsPatientsTherapyResectionMonthsOutcomesHNSCCSurgeryCarcinomaHeadIncidenceProgressionClinical Outcomes of Head and Neck Cancer Patients who Undergo Resection, but Forgo Adjuvant Therapy
Loganadane G, Kann B, Park H, Johnson S, Mehra S, Judson B, Bhatia A, Belkacemi Y, Yarbrough W, Burtness B, Husain Z. Clinical Outcomes of Head and Neck Cancer Patients who Undergo Resection, but Forgo Adjuvant Therapy. International Journal Of Radiation Oncology • Biology • Physics 2019, 105: e375-e376. DOI: 10.1016/j.ijrobp.2019.06.1628.Peer-Reviewed Original Research
2018
Adjuvant Chemotherapy Is Associated With Improved Survival for Late‐Stage Salivary Squamous Cell Carcinoma
Cheraghlou S, Schettino A, Zogg CK, Otremba MD, Bhatia A, Park HS, Osborn HA, Mehra S, Yarbrough WG, Judson BL. Adjuvant Chemotherapy Is Associated With Improved Survival for Late‐Stage Salivary Squamous Cell Carcinoma. The Laryngoscope 2018, 129: 883-889. PMID: 30151947, DOI: 10.1002/lary.27444.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, Squamous CellChemoradiotherapy, AdjuvantChemotherapy, AdjuvantCombined Modality TherapyFemaleHumansKaplan-Meier EstimateMaleMiddle AgedNeoplasm StagingPropensity ScoreProportional Hazards ModelsRadiotherapy, AdjuvantRetrospective StudiesSalivary Gland NeoplasmsSurvival RateTreatment OutcomeConceptsLate-stage patientsSquamous cell carcinomaAdjuvant radiotherapyAdjuvant therapyAdjuvant chemoradiotherapyAdjuvant chemotherapyImproved survivalCell carcinomaImproved long-term survivalCox survival regressionPrimary cutaneous malignanciesUnique disease entityAddition of chemotherapyNational Cancer DatabaseEarly-stage diseaseFive-year survivalEarly-stage patientsKaplan-Meier analysisParotid gland cancerLate stage groupLong-term survivalSurvival benefitCutaneous malignanciesPoor prognosisRetrospective studyEpigenetic Changes and Epigenetic Targets in Head and Neck Cancer
Peri S, Andrews A, Bhatia A, Mehra R. Epigenetic Changes and Epigenetic Targets in Head and Neck Cancer. Current Cancer Research 2018, 327-352. DOI: 10.1007/978-3-319-78762-6_12.Peer-Reviewed Original ResearchEpigenetic changesRepression of genesEpigenetic control systemsGene expression patternsModification of DNAEpigenetic controlEpigenetic regulationEpigenetic modificationsEpigenetic targetsTranscriptional activityKey proteinsExpression patternsGene expressionDNASelective inductionDisease pathologySpatial conformationHistonesRepressionGenesProteinTumor DNARegulationModificationExpression